OncoSec Medical

OncoSec establishes UCSF clinical site for phase II Merkel cell carcinoma trial

Wednesday, July 11, 2012 10:22 AM

OncoSec Medical, a biopharmaceutical company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, has established the University of California San Francisco (UCSF) as the second enrolling site for its phase II Merkel cell carcinoma study (OMS-I110).

More... »


OncoSec doses first patients in phase II Merkel cell carcinoma study

Monday, February 13, 2012 03:22 PM

OncoSec Medical has treated several patients in an open-label, phase II clinical trial evaluating OncoSec's OMS (OncoSec Medical System) ElectroImmunotherapy for the treatment of Merkel cell carcinoma (MCC).

More... »


OncoSec names Brain McCluskey engineering leader

Wednesday, July 6, 2011 10:50 AM

OncoSec Medical has named Brian McCluskey executive director of engineering, to lead the development of the company's proprietary electroporation delivery technology, the OncoSec Medical System (OMS).

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs